WallStreetZenWallStreetZen

NASDAQ: SNDX
Syndax Pharmaceuticals Inc Stock

$21.35+1.66 (+8.43%)
Updated Nov 6, 2024
SNDX Price
$21.35
Fair Value Price
$4.17
Market Cap
$1.82B
52 Week Low
$13.14
52 Week High
$25.34
P/E
-5.87x
P/B
4.97x
P/S
102.79x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.00M
Earnings
-$297.06M
Gross Margin
100%
Operating Margin
-1,855.48%
Profit Margin
-1,856.6%
Debt to Equity
0.16
Operating Cash Flow
-$259M
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

SNDX Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SNDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SNDX ($21.35) is overvalued by 411.44% relative to our estimate of its Fair Value price of $4.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SNDX ($21.35) is not significantly undervalued (411.44%) relative to our estimate of its Fair Value price of $4.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SNDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SNDX due diligence checks available for Premium users.

Be the first to know about important SNDX news, forecast changes, insider trades & much more!

SNDX News

Valuation

SNDX fair value

Fair Value of SNDX stock based on Discounted Cash Flow (DCF)
Price
$21.35
Fair Value
$4.17
Overvalued by
411.44%
SNDX ($21.35) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SNDX ($21.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SNDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SNDX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.87x
Industry
-126.66x
Market
24.29x

SNDX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.97x
Industry
5.7x
SNDX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SNDX's financial health

Profit margin

Revenue
$12.5M
Net Income
-$84.1M
Profit Margin
-673%
SNDX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SNDX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$425.8M
Liabilities
$59.4M
Debt to equity
0.16
SNDX's short-term assets ($414.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNDX's short-term assets ($414.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNDX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SNDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$62.3M
Investing
$86.8M
Financing
$3.1M
SNDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SNDX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SNDX$1.82B+8.43%-5.87x4.97x
CLDX$1.83B+8.65%-10.05x2.25x
CNTA$1.81B-0.06%-10.32x6.31x
TARS$1.78B+2.50%-10.54x7.06x
GLPG$1.78B+0.97%N/A0.58x

Syndax Pharmaceuticals Stock FAQ

What is Syndax Pharmaceuticals's quote symbol?

(NASDAQ: SNDX) Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol SNDX. Syndax Pharmaceuticals stock quotes can also be displayed as NASDAQ: SNDX.

If you're new to stock investing, here's how to buy Syndax Pharmaceuticals stock.

What is the 52 week high and low for Syndax Pharmaceuticals (NASDAQ: SNDX)?

(NASDAQ: SNDX) Syndax Pharmaceuticals's 52-week high was $25.34, and its 52-week low was $13.14. It is currently -15.75% from its 52-week high and 62.48% from its 52-week low.

How much is Syndax Pharmaceuticals stock worth today?

(NASDAQ: SNDX) Syndax Pharmaceuticals currently has 85,357,675 outstanding shares. With Syndax Pharmaceuticals stock trading at $21.35 per share, the total value of Syndax Pharmaceuticals stock (market capitalization) is $1.82B.

Syndax Pharmaceuticals stock was originally listed at a price of $12.01 in Mar 3, 2016. If you had invested in Syndax Pharmaceuticals stock at $12.01, your return over the last 8 years would have been 77.77%, for an annualized return of 7.46% (not including any dividends or dividend reinvestments).

How much is Syndax Pharmaceuticals's stock price per share?

(NASDAQ: SNDX) Syndax Pharmaceuticals stock price per share is $21.35 today (as of Nov 6, 2024).

What is Syndax Pharmaceuticals's Market Cap?

(NASDAQ: SNDX) Syndax Pharmaceuticals's market cap is $1.82B, as of Nov 7, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Syndax Pharmaceuticals's market cap is calculated by multiplying SNDX's current stock price of $21.35 by SNDX's total outstanding shares of 85,357,675.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.